-
1
-
-
0020634337
-
An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls
-
Clague H.W., Twum-Barima Y., and Carruthers S.G. An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit 5 (1983) 249-254
-
(1983)
Ther Drug Monit
, vol.5
, pp. 249-254
-
-
Clague, H.W.1
Twum-Barima, Y.2
Carruthers, S.G.3
-
2
-
-
0018817836
-
Basic issues in population screening for cancer
-
Cole P., and Morrison A.S. Basic issues in population screening for cancer. J Natl Cancer Inst 64 (1980) 1263-1272
-
(1980)
J Natl Cancer Inst
, vol.64
, pp. 1263-1272
-
-
Cole, P.1
Morrison, A.S.2
-
3
-
-
0032932453
-
Is 'routine' laboratory testing a thing of the past? Current recommendations regarding screening
-
quiz 227
-
Tabas G.H., and Vanek M.S. Is 'routine' laboratory testing a thing of the past? Current recommendations regarding screening. Postgrad Med 105 (1999) 213-220 quiz 227
-
(1999)
Postgrad Med
, vol.105
, pp. 213-220
-
-
Tabas, G.H.1
Vanek, M.S.2
-
4
-
-
21344460229
-
How to interpret and pursue an abnormal complete blood cell count in adults
-
Tefferi A., Hanson C.A., and Inwards D.J. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 80 (2005) 923-936
-
(2005)
Mayo Clin Proc
, vol.80
, pp. 923-936
-
-
Tefferi, A.1
Hanson, C.A.2
Inwards, D.J.3
-
5
-
-
0036138009
-
Yield and cost of individual common diagnostic tests in new primary care outpatients in Japan
-
Takemura Y., Ishida H., Inoue Y., and Beck J.R. Yield and cost of individual common diagnostic tests in new primary care outpatients in Japan. Clin Chem 48 (2002) 42-54
-
(2002)
Clin Chem
, vol.48
, pp. 42-54
-
-
Takemura, Y.1
Ishida, H.2
Inoue, Y.3
Beck, J.R.4
-
6
-
-
0038680231
-
Utilization of common inflammatory markers in new, symptomatic, primary care outpatients based on their cost-effectiveness
-
Takemura Y., Ishida H., and Inoue Y. Utilization of common inflammatory markers in new, symptomatic, primary care outpatients based on their cost-effectiveness. Clin Chem Lab Med 41 (2003) 668-674
-
(2003)
Clin Chem Lab Med
, vol.41
, pp. 668-674
-
-
Takemura, Y.1
Ishida, H.2
Inoue, Y.3
-
7
-
-
0030317476
-
Clinical approach to the patient with abnormal liver test results
-
quiz 1094-5
-
Kamath P.S. Clinical approach to the patient with abnormal liver test results. Mayo Clin Proc 71 (1996) 1089-1094 quiz 1094-5
-
(1996)
Mayo Clin Proc
, vol.71
, pp. 1089-1094
-
-
Kamath, P.S.1
-
8
-
-
0035954670
-
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
-
Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
-
(2001)
N Engl J Med
, vol.345
, pp. 248-255
-
-
Ellis, C.N.1
Krueger, G.G.2
-
9
-
-
0036895587
-
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
-
Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., and Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
-
(2002)
J Am Acad Dermatol
, vol.47
, pp. 821-833
-
-
Krueger, G.G.1
Papp, K.A.2
Stough, D.B.3
Loven, K.H.4
Gulliver, W.P.5
Ellis, C.N.6
-
10
-
-
0043135118
-
Development and use of alefacept to treat psoriasis
-
Krueger G.G., and Callis K.P. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 49 2 Suppl (2003) S87-S97
-
(2003)
J Am Acad Dermatol
, vol.49
, Issue.2 SUPPL
-
-
Krueger, G.G.1
Callis, K.P.2
-
11
-
-
33646589648
-
The long-term efficacy and safety of new biological therapies for psoriasis
-
Papp K.A. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res (2006)
-
(2006)
Arch Dermatol Res
-
-
Papp, K.A.1
-
12
-
-
0038385972
-
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
-
Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., and Griffiths C.E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
-
(2003)
Arch Dermatol
, vol.139
, pp. 719-727
-
-
Lebwohl, M.1
Christophers, E.2
Langley, R.3
Ortonne, J.P.4
Roberts, J.5
Griffiths, C.E.6
-
13
-
-
0348134794
-
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts
-
Gordon K.B., Vaishnaw A.K., O'Gorman J., Haney J., and Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 139 (2003) 1563-1570
-
(2003)
Arch Dermatol
, vol.139
, pp. 1563-1570
-
-
Gordon, K.B.1
Vaishnaw, A.K.2
O'Gorman, J.3
Haney, J.4
Menter, A.5
-
14
-
-
29244464655
-
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
-
Menter A., Cather J.C., Baker D., Farber H.F., Lebwohl M., and Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
-
(2006)
J Am Acad Dermatol
, vol.54
, pp. 61-63
-
-
Menter, A.1
Cather, J.C.2
Baker, D.3
Farber, H.F.4
Lebwohl, M.5
Darif, M.6
-
15
-
-
49849096102
-
-
alefacept product monograph. 2003.
-
alefacept product monograph. 2003.
-
-
-
-
16
-
-
11844281451
-
Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator
-
Papp K.A. Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator. Drugs Today (Barc) 40 (2004) 889-899
-
(2004)
Drugs Today (Barc)
, vol.40
, pp. 889-899
-
-
Papp, K.A.1
-
17
-
-
0346515709
-
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
-
Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama 290 (2003) 3073-3080
-
(2003)
Jama
, vol.290
, pp. 3073-3080
-
-
Gordon, K.B.1
Papp, K.A.2
Hamilton, T.K.3
-
18
-
-
1842591940
-
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis
-
Menter A., Kosinski M., Bresnahan B.W., Papp K.A., and Ware Jr. J.E. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 3 (2004) 27-38
-
(2004)
J Drugs Dermatol
, vol.3
, pp. 27-38
-
-
Menter, A.1
Kosinski, M.2
Bresnahan, B.W.3
Papp, K.A.4
Ware Jr., J.E.5
-
19
-
-
33646167222
-
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
-
Papp K.A., Bressinck R., Fretzin S., et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 45 (2006) 605-614
-
(2006)
Int J Dermatol
, vol.45
, pp. 605-614
-
-
Papp, K.A.1
Bressinck, R.2
Fretzin, S.3
-
20
-
-
33745038011
-
Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial
-
Dubertret L., Sterry W., Bos J.D., et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155 (2006) 170-181
-
(2006)
Br J Dermatol
, vol.155
, pp. 170-181
-
-
Dubertret, L.1
Sterry, W.2
Bos, J.D.3
-
21
-
-
0345107256
-
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
-
Lebwohl M., Tyring S.K., Hamilton T.K., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
-
(2003)
N Engl J Med
, vol.349
, pp. 2004-2013
-
-
Lebwohl, M.1
Tyring, S.K.2
Hamilton, T.K.3
-
22
-
-
12444336904
-
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
-
Menter A., Gordon K., Carey W., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
-
(2005)
Arch Dermatol
, vol.141
, pp. 31-38
-
-
Menter, A.1
Gordon, K.2
Carey, W.3
-
23
-
-
32544449299
-
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial
-
Gottlieb A.B., Hamilton T., Caro I., Kwon P., Compton P.G., and Leonardi C.L. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54 4 Suppl 1 (2006) S154-S163
-
(2006)
J Am Acad Dermatol
, vol.54
, Issue.4 SUPPL. 1
-
-
Gottlieb, A.B.1
Hamilton, T.2
Caro, I.3
Kwon, P.4
Compton, P.G.5
Leonardi, C.L.6
-
24
-
-
32544433436
-
Long-term management of plaque psoriasis with continuous efalizumab therapy
-
Menter A., Leonardi C.L., Sterry W., Bos J.D., and Papp K.A. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 54 4 Suppl 1 (2006) S182-S188
-
(2006)
J Am Acad Dermatol
, vol.54
, Issue.4 SUPPL. 1
-
-
Menter, A.1
Leonardi, C.L.2
Sterry, W.3
Bos, J.D.4
Papp, K.A.5
-
25
-
-
33749330192
-
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II
-
Papp K.A., Camisa C., Stone S.P., et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II. J Cutan Med Surg 9 (2006) 213-323
-
(2006)
J Cutan Med Surg
, vol.9
, pp. 213-323
-
-
Papp, K.A.1
Camisa, C.2
Stone, S.P.3
-
26
-
-
49849083822
-
-
Raptiva (efalizumab) package insert. In: Genentech I, ed. Vol. 2007. South San Francisco; 2006.
-
Raptiva (efalizumab) package insert. In: Genentech I, ed. Vol. 2007. South San Francisco; 2006.
-
-
-
-
27
-
-
32544441226
-
Relapse, rebound, and psoriasis adverse events: an advisory group report
-
Carey W., Glazer S., Gottlieb A.B., et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 54 4 Suppl 1 (2006) S171-S181
-
(2006)
J Am Acad Dermatol
, vol.54
, Issue.4 SUPPL. 1
-
-
Carey, W.1
Glazer, S.2
Gottlieb, A.B.3
-
28
-
-
17144388751
-
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
-
Leonardi C.L., Papp K.A., Gordon K.B., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
-
(2005)
J Am Acad Dermatol
, vol.52
, pp. 425-433
-
-
Leonardi, C.L.1
Papp, K.A.2
Gordon, K.B.3
-
29
-
-
32544448638
-
Practical guidelines for the long-term treatment of psoriasis with efalizumab
-
Leonardi C.L., Papp K.A., and Bos J.D. Practical guidelines for the long-term treatment of psoriasis with efalizumab. J Am Acad Dermatol 54 (2006) S153
-
(2006)
J Am Acad Dermatol
, vol.54
-
-
Leonardi, C.L.1
Papp, K.A.2
Bos, J.D.3
-
30
-
-
36148994531
-
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
-
Lowes M.A., Chamian F., Abello M.V., et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol 7 (2007) 2
-
(2007)
BMC Dermatol
, vol.7
, pp. 2
-
-
Lowes, M.A.1
Chamian, F.2
Abello, M.V.3
-
31
-
-
33747368253
-
Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis
-
Papp K.A., Ho V., Langley R., et al. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg 9 Suppl 1 (2005) 26-32
-
(2005)
J Cutan Med Surg
, vol.9
, Issue.SUPPL. 1
, pp. 26-32
-
-
Papp, K.A.1
Ho, V.2
Langley, R.3
-
32
-
-
49849092124
-
-
Product Monograph Part III: Raptiva. 2005.
-
Product Monograph Part III: Raptiva. 2005.
-
-
-
-
33
-
-
0027490541
-
Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor
-
Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 (1993) 354-362
-
(1993)
Clin Exp Immunol
, vol.94
, pp. 354-362
-
-
Kristensen, M.1
Chu, C.Q.2
Eedy, D.J.3
Feldmann, M.4
Brennan, F.M.5
Breathnach, S.M.6
-
34
-
-
0142072978
-
TNFalpha as therapeutic target: new drugs, more applications
-
Reimold A.M. TNFalpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 1 (2002) 377-392
-
(2002)
Curr Drug Targets Inflamm Allergy
, vol.1
, pp. 377-392
-
-
Reimold, A.M.1
-
35
-
-
15944428248
-
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis
-
Tobin A.M., and Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19 (2005) 47-57
-
(2005)
BioDrugs
, vol.19
, pp. 47-57
-
-
Tobin, A.M.1
Kirby, B.2
-
36
-
-
21644481166
-
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
-
Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312
-
(2005)
Br J Dermatol
, vol.152
, pp. 1304-1312
-
-
Papp, K.A.1
Tyring, S.2
Lahfa, M.3
-
37
-
-
0344926414
-
Etanercept as monotherapy in patients with psoriasis
-
Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
-
(2003)
N Engl J Med
, vol.349
, pp. 2014-2022
-
-
Leonardi, C.L.1
Powers, J.L.2
Matheson, R.T.3
-
38
-
-
49849083149
-
-
European Medicines Agency. Enbrel [etanercept] summary of product characteristics.
-
European Medicines Agency. Enbrel [etanercept] summary of product characteristics.
-
-
-
-
39
-
-
49849087011
-
-
http://www.emea.eu.int/humandocs/Humans/EPAR/enbrel/enbrel.htm. Accessed 2005.
-
http://www.emea.eu.int/humandocs/Humans/EPAR/enbrel/enbrel.htm. Accessed 2005.
-
-
-
-
40
-
-
34250761386
-
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
-
Tyring S., Gordon K.B., Poulin Y., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
-
(2007)
Arch Dermatol
, vol.143
, pp. 719-726
-
-
Tyring, S.1
Gordon, K.B.2
Poulin, Y.3
-
41
-
-
0038456045
-
Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis
-
Gottlieb A.B., Chaudhari U., Mulcahy L.D., Li S., Dooley L.T., and Baker D.G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 48 (2003) 829-835
-
(2003)
J Am Acad Dermatol
, vol.48
, pp. 829-835
-
-
Gottlieb, A.B.1
Chaudhari, U.2
Mulcahy, L.D.3
Li, S.4
Dooley, L.T.5
Baker, D.G.6
-
42
-
-
4644327125
-
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
-
Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 534-542
-
-
Gottlieb, A.B.1
Evans, R.2
Li, S.3
-
43
-
-
0043135095
-
Infliximab for psoriasis
-
Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol 49 2 Suppl (2003) S112-S117
-
(2003)
J Am Acad Dermatol
, vol.49
, Issue.2 SUPPL
-
-
Gottlieb, A.B.1
-
44
-
-
26644433889
-
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
-
Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
-
(2005)
Lancet
, vol.366
, pp. 1367-1374
-
-
Reich, K.1
Nestle, F.O.2
Papp, K.3
-
45
-
-
33646379583
-
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial
-
Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1075-1086
-
(2006)
Arthritis Rheum
, vol.54
, pp. 1075-1086
-
-
Westhovens, R.1
Yocum, D.2
Han, J.3
-
46
-
-
33845188387
-
Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment
-
Hyder S.A., Travis S.P., Jewell D.P., Mc C.M.N.J., and George B.D. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 49 (2006) 1837-1841
-
(2006)
Dis Colon Rectum
, vol.49
, pp. 1837-1841
-
-
Hyder, S.A.1
Travis, S.P.2
Jewell, D.P.3
Mc, C.M.N.J.4
George, B.D.5
-
47
-
-
49849105371
-
-
Remicade (infliximab) package insert. Vol. 2007: Centocor; 2006.
-
Remicade (infliximab) package insert. Vol. 2007: Centocor; 2006.
-
-
-
-
48
-
-
49849087907
-
-
Hepatitis B reactivation associated with the anti-TNF products, Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab). In: Authrotiy NZMa MDS, ed: The Ministry of Health, New Zealand; 2006.
-
Hepatitis B reactivation associated with the anti-TNF products, Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab). In: Authrotiy NZMa MDS, ed: The Ministry of Health, New Zealand; 2006.
-
-
-
-
49
-
-
22544436130
-
Reactivation of latent granulomatous infections by infliximab
-
Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 Suppl 3 (2005) S194-S198
-
(2005)
Clin Infect Dis
, vol.41
, Issue.SUPPL. 3
-
-
Wallis, R.S.1
Broder, M.2
Wong, J.3
Lee, A.4
Hoq, L.5
|